Abstracts - PAGE Meeting (Population Approach Group Europe)

← Back to filters

Abstracts (34)

A-03Jeremie Guedj

Pharmacometrics to support clinical investigation during COVID-19 pandemics : a viral dynamics perspective

Thursday 13:10-13:55

A-03France Mentré

Pharmacometrics to support clinical investigation during COVID-19 pandemics

Thursday 13:10-13:55

A-04Thorsten Lehr

Modeling and Simulation of SARS-CoV-2 Infections, Hospitalizations and Outcome in Germany

Thursday 13:55-14:40

A-08Nadege Neant

Modeling SARS-CoV-2 viral kinetics in hospitalized patients

Thursday 15:45-16:05

A-09Mélanie Prague

Using population approach to model COVID-19 epidemics in France: estimating the burden of SARS-Cov-2 and the effects of non-pharmaceutical interventions.

Thursday 16:05-16:25

A-10Seth Robey

Predictive Primates: Enabling Rapid Go/No-Go Decisions on COVID-19 Vaccine Candidates with a Predictive, Translational MBMA and Clinical Immunogenicity Data

Thursday 16:25-16:45

A-13Andrew Hooker

Tutorial on survival analysis and its application to the assessment of competing risks in clinical data analysis.

Thursday 16:55-17:10

A-14Joachim Grevel

Tutorial on application of survival analysis to the assessment of multiple state models in clinical data analysis.

Thursday 17:10-17:40

B-03Rob van Wijk

Translational quantitative systems pharmacology; crossing borders between experimental and computational drug development using zebrafish as model organism

Friday 13:00-13:25

B-04Eleni Karatza

Machine-Learning for cancer treatment: Guided covariate selection for TTE models developed from real world data with a small number of patients

Friday 13:25-13:50

B-05Vincent Chang

In silico assessment of adaptive trial design for TB regimen development

Friday 13:50-14:15

B-10Linda Aulin

Model-based design of innovative treatment strategies to suppress antimicrobial resistance using collateral sensitivity

Friday 15:30-15:55

B-11Marion Kerioui

Bayesian modelling of individual lesions dynamics and survival to characterize response to immunotherapy cancer treatments

Friday 15:55-16:20

B-12Anna Mc Laughlin

Population quantitative systems pharmacology model of distinct CAR-T cell phenotypes and CD19-specific metabolic tumour volume reveals sources of high pharmacokinetic variability and overall survival

Friday 16:20-16:45

B-16Alexander Janssen

The Neural Mixed Effects algorithm: leveraging machine learning for pharmacokinetic modelling

Friday 17:00-17:20

B-17James Lu

Deep Learning for PK/PD and Disease Progression Time-Course Predictions using Neural-ODE

Friday 17:20-17:40

C-03Vladimir Dragalin

Adaptive trial designs: opportunities and challenges

Monday 13:00-13:45

C-07Anyue Yin

Anti-cancer treatment schedule optimization based on tumor dynamics modelling incorporating evolving resistance

Monday 14:00-14:20

C-08Sreenath M Krishnan

Multistate model for pharmacometric analyses of overall survival in anticancer treatments

Monday 14:20-14:40

C-09René Bruno

Operating characteristics of tumor growth inhibition-overall survival models to support early Phase Ib decisions: An evaluation in first-line metastatic non-small cell lung cancer patients treated with atezolizumab plus chemotherapy based on the Phase III study IMpower150

Monday 14:40-15:00

C-12Verena Gotta

Personalizing hemodialysis (HD) treatment in pediatric patients with end-stage renal disease (ESRD) – application and integration of quantitative pharmacology with machine learning

Monday 16:00-16:20

C-13Jasmine Hughes

A hybrid machine learning/pharmacokinetic approach improves predictive performance in model-informed precision dosing

Monday 16:20-16:40

C-14Diego Vera-Yunca

Semi-mechanistic modeling of tumor size and overall survival including machine learning-derived tumor heterogeneity

Monday 16:40-17:00

C-17Nicolás Marco Ariño

The broad use of pharmacometrics in patient care: the case of blood transfusion and perioperative management

Monday 17:05-17:25

C-18Estelle Yau

A systematic framework for the incorporation of preclinical species data into physiologically-based pharmacokinetic models using a middle-out approach to improve the translation of drug distribution in humans

Monday 17:25-17:45

D-03Carolina Llanos-Paez

Use of item-based non-linear mixed effects model to improve confidence in Phase III clinical trial decision-making

Tuesday 13:00-13:20

D-04Iris Minichmayr

Beyond disease progression – Item response theory modelling to gain structural insights into disease facets underlying clinical score assessments

Tuesday 13:20-13:40

D-05Alexandra Lavalley-Morelle

Individual dynamic predictions in joint analysis for nonlinear marker evolution and competing risk data: application on patients admitted in Intensive Care Unit for sepsis

Tuesday 13:40-14:00

D-09Zoe Kane

Development of a neonatal plasma and cerebrospinal fluid (CSF) population PK model for fosfomycin.

Tuesday 14:30-14:50

D-10David Busse

Body composition and drug exposure in adipose tissue are key for antibiotic dose-individualisation in obese individuals

Tuesday 14:50-15:10

D-11Jérémy Seurat

Combination of in vivo phage therapy data with in silico model highlights key parameters for treatment efficacy

Tuesday 15:10-15:30

D-14Roeland Wasmann

A pharmacometric approach to optimise Fixed-Dose Combinations of Rifampicin, Isoniazid, and Pyrazinamide for children with tuberculosis

Tuesday 16:15-17:35

D-15Marie Alexandre

Dynamics of the humoral immune response to a two-dose heterologous vaccine regimen against Ebola virus.

Tuesday 16:35-16:55

D-16João Abrantes

Model-informed development of RG6102, an amyloid-targeting investigational drug with enhanced brain penetration properties

Tuesday 16:55-17:15